Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Results from an ongoing Phase 2 study in pregnant individuals showed the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants The safety profile between the vaccine and placebo groups was similar in both the mothers and infants GBS6 maternal vaccination may offer meaningful protection against invasive GBS disease in newborns and young infants, based on a natural history study conducted in parallel to the Phase 2 study
Source: marketscreener.com